Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 6, pp 1464–1476 | Cite as

Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life

  • Nibal AbunahlahEmail author
  • Mesut Sancar
  • Faysal Dane
  • Mustafa Kerem Özyavuz
Research Article

Abstract

Background International guidelines are tools enabling physicians to incorporate the latest evidence based clinical information into practice. Objective This study aimed to evaluate the impact of antiemetic guidelines adherence on the incidence of chemotherapy-induced nausea and vomiting (CINV) and patient quality of life. Setting Marmara University Pendik Training and Research Hospital chemotherapy unit, Istanbul, Turkey. Method The study included 100 chemotherapy naive patients. Antiemetic prescribing patterns and their consistency with MASCC/ESMO 2014 guidelines were assessed. Patients recorded incidences of vomiting in a daily dairy and described their nausea using a 7-item Likert Scale. The incidence of CINV was recorded over five days. To assess the patient's quality of life, a modified Turkish version of the Functional Living Index-Emesis (FLIE) questionnaire was administered before and after receiving chemotherapy. A questionnaire on the existence and severity of side effects was developed and administered. Main outcome measures Incidence of side effects on CINV and quality of life according to the FLIE. Results The primary outcome revealed differences in complete control (no emetic episodes, rescue therapy or nausea), FLIE scores and side effects. Guidelines consistency was observed more with acute (A) than with delayed (D) prevention of CINV, with significant differences in complete control between the guideline adherent group (GAG) and the guideline nonadherent group (GNG). Significant differences in the FLIE score were noticed between GAG(D) and GNG(D), and GNG(D) had a higher incidence of diarrhoea, headache, swallowing difficulties and dark-coloured stool. Conclusion Consistency with guidelines resulted in significant reduction in the incidence of both cute and delayed CINV and other side effects, and with improvement of the patient quality of life.

Keywords

Adverse drug reaction Chemotherapy Guideline Nausea Quality of life Vomiting 

Notes

Acknowledgements

The authors are grateful to Merve Sarı who assisted in identifying patients.

Funding

None.

Conflicts of interest

The authors have no conflicts of interest to declare.

Supplementary material

11096_2016_393_MOESM1_ESM.docx (59 kb)
Supplementary material 1 (DOCX 58 kb)

References

  1. 1.
    Herrstedt J. Nausea and emesis: Still an unsolved problem in cancer patients? Support Care Cancer. 2002;10:85–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Tina Shih Y, Xu Y, Elting L. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110:678–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Lindley CM, Hirsch JD. Nausea and vomiting and cancer patients’ quality of life: a discussion of Professor Selby’s paper. Br J Cancer. 1992;19:S26–9.Google Scholar
  4. 4.
    Bloechl-Daum B. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, et al. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer. 2006;15:179–85.CrossRefPubMedGoogle Scholar
  6. 6.
    Cohen L, de Moor C, Eisenberg P, Ming E, Hu H. Chemotherapy-induced nausea and vomiting incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2006;15:497–503.CrossRefPubMedGoogle Scholar
  7. 7.
    Fernandez-Ortega P, Caloto M, Chirveches E, Marquilles R, Francisco J, Quesada A, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life. Support Care Cancer. 2012;20:3141–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Jordan NS, Schauer PK, Schauer A, Nightingale C, Golub G, Martin RS, et al. The effect of administration rate on cisplatin-induced emesis. J Clin Oncol. 1985;3:559–61.PubMedGoogle Scholar
  9. 9.
    Basch E, Hesketh P, Kris M, Prestrud A, Temin S, Lyman G. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. JOP. 2011;7:395–8.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Roila F, Herrstedt J, Aapro M, Gralla R, Einhorn L, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21:232–43.CrossRefGoogle Scholar
  11. 11.
    Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB, et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park). 1998;12:32–7.Google Scholar
  12. 12.
    Kirkova J, Rybicki L, Walsh D, Aktas A. Symptom prevalence in advanced cancer: age, gender, and performance status interactions. Am J Hosp Palliat Med. 2011;29:139–45.CrossRefGoogle Scholar
  13. 13.
    Kaiser R. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002;20:2805–11.CrossRefPubMedGoogle Scholar
  14. 14.
    Tremblay P. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol. 2003;21:2147–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Morrow G, Roscoe J, Kirshner J, Hynes H, Rosenbluth R. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer. 1998;6:244–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Fallowfield L. Behavioural interventions and psychological aspects of care during chemotherapy. Eur J Cancer. 1992;28:S39–41.CrossRefGoogle Scholar
  17. 17.
    Morrow G. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer. 1985;55:2766–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197–202.CrossRefPubMedGoogle Scholar
  19. 19.
    Peterson C, Hursti T, Barjeson S, Ãvall-Lundgvist E, Fredrikson M, Farst C, et al. Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer. 1996;4:440–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Gralla R. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Aksu G, Dolasik I, Ensaroglu F, Sener S, Aydin F, Temiz S, et al. Evaluation of the efficacy of aprepitant on the prevention of chemotherapy-induced nausea and vomiting and quality of life with functional living index emesis. Balk Med J. 2013;30:64–7.CrossRefGoogle Scholar
  22. 22.
    Berger AM, Clark-Snow RA. Nausea and vomiting. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.Google Scholar
  23. 23.
    Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol. 1998;16:2937–42.Google Scholar
  24. 24.
    McCrea J. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17–24.CrossRefPubMedGoogle Scholar
  25. 25.
    Hesketh P. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J Clin Oncol. 2003;21:4112–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides A, Julie Ma G, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:3090–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Warr D. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2004;23:2822–30.CrossRefGoogle Scholar
  28. 28.
    Olver I, Paska W, Depierre A, Seitz J, Stewart D, Goedhals L, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol. 1996;7:945–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol. 1995;13:2408–16.PubMedGoogle Scholar
  30. 30.
    Goedhals L, Heron J, Kleisbauer J, Pagani O, Sessa C. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly comparative study. Ann Oncol. 1998;9:661–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Geling O. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23:1289–94.CrossRefPubMedGoogle Scholar
  32. 32.
    Aapro M. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115–24.CrossRefPubMedGoogle Scholar
  34. 34.
    Chan A, Shih V, Chew L. Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre. J Oncol Pharm Pract. 2008;14:23–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer. 2003;98:2473–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Likun Z, Xiang J, Yi B, Xin D, Tao Z. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist. 2011;16:207–16.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Fujii H, Iihara H, Ishihara M, Takahashi T, Yoshida K, Itoh Y. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk. Anticancer Res. 2013;33:5549–56.PubMedGoogle Scholar
  38. 38.
    Almazrou S, Alnaim L. Evaluation of adherence to chemotherapy-induced nausea and vomiting guidelines. An Observational Study. J Cancer Ther. 2012;3:613–20.CrossRefGoogle Scholar
  39. 39.
    Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23:1986–92.CrossRefPubMedGoogle Scholar
  40. 40.
    Gilmore J, Peacock N, Gu A, Szabo S, Rammage M, Sharpe J, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. JOP. 2013;10:68–74.PubMedGoogle Scholar
  41. 41.
    Goodin S. 5-HT3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist. 2002;7:424–36.CrossRefPubMedGoogle Scholar
  42. 42.
    Meyerowitz B, Sparks F, Spears I. Adjuvant chemotherapy for breast carcinoma: psychosocial implications. Cancer. 1979;43:1613–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  1. 1.Department of Clinical Pharmacy, School of PharmacyIstanbul Kemerburgaz UniversityIstanbulTurkey
  2. 2.Department of Clinical Pharmacy, School of PharmacyMarmara UniversityIstanbulTurkey
  3. 3.Department of Internal Medicine, Division of Medical Oncology, School of MedicineMarmara UniversityIstanbulTurkey
  4. 4.Molecular Medicine Department, Division of Hospital ManagementMarmara University Pendik Training and Research HospitalIstanbulTurkey

Personalised recommendations